Dose, Formulation, and Route
Dose, formulation, and route are product-identity fields. They help distinguish regulated products, label versions, delivery formats, and clinical programs in obesity-treatment records.
These fields should not be used as dosing advice. Weight Loss Index describes how products and programs are structured in the industry. It does not tell readers what dose to use, how to take a medicine, whether to switch products, or how to interpret an individual treatment plan.
The basic distinction
Section titled “The basic distinction”| Field | Practical meaning | Why it matters |
|---|---|---|
| Dose | The amount of active ingredient in a labeled or studied regimen | Helps distinguish trial arms, dose-escalation schedules, maintenance doses, and product labels |
| Strength | The amount of active ingredient in a dosage unit or presentation | Helps identify product presentations, pens, tablets, capsules, or other supplied forms |
| Formulation | How the active ingredient is prepared and delivered in a product | Helps distinguish injectable, oral, extended-release, fixed-dose, or other product designs |
| Dosage form | The physical or pharmaceutical form, such as injection, tablet, or capsule | Helps connect product records to route, label, manufacturing, and access context |
| Route of administration | How the product is administered, such as subcutaneous injection or oral administration | Helps compare product design without implying clinical equivalence |
| Device or presentation | The supplied delivery system or packaging, when relevant | Helps explain product access, dispensing, supply, and user-facing product identity |
These details are part of a product’s regulated identity. They should be attached to a product, label, clinical trial, market, date, and source.
Why these fields matter
Section titled “Why these fields matter”Obesity-treatment products can share an active ingredient or broad mechanism while differing in formulation and route. Semaglutide appears across products with different product identities and market roles. Tirzepatide also appears across separate obesity and diabetes products. Orlistat appears in prescription and nonprescription product contexts.
Those distinctions affect database mapping. A product page may need to distinguish brand, active ingredient, route, dosage form, label, sponsor, approval history, market, and access context. An ingredient page may connect several products without treating them as the same medicine.
Clinical trials and labels use dose differently
Section titled “Clinical trials and labels use dose differently”Clinical trial records may describe studied doses, dose escalation, treatment arms, comparators, and duration. Product labels describe approved product information in a jurisdiction. Those are related sources, but they are not interchangeable.
A studied dose in a trial does not by itself establish an approved dose. A label dose does not summarize every clinical development record. A dose or formulation from one product should not be transferred to another product without product-specific source support.
Obesity-treatment examples
Section titled “Obesity-treatment examples”| Product context | Interpretation point |
|---|---|
| Wegovy and Ozempic both involve semaglutide | Shared active ingredient does not make the products identical; product-specific labels, indications, routes, strengths, and market roles still matter |
| Zepbound and Mounjaro both involve tirzepatide | Ingredient-level mapping should not collapse separate product and label records |
| Rybelsus is an oral semaglutide product in a diabetes context | Route and indication context can make an adjacent product relevant to obesity-treatment research without making it a core obesity product |
| Xenical and Alli both involve orlistat | Prescription and nonprescription product contexts should be distinguished by product, strength, label, and distribution setting |
What not to infer
Section titled “What not to infer”A shared dose unit does not mean comparable clinical effect. A shared route does not mean shared indication. A shared formulation concept does not mean products are interchangeable. A clinical trial regimen does not establish personal dosing guidance. A label in one jurisdiction does not automatically apply elsewhere.
Dose, formulation, and route should support product identification, clinical-program interpretation, and regulatory mapping. They should not become treatment instructions.